Close Close
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards

Life Health > Health Insurance

J&J raises 2016 profit forecast after drug sales increase

Your article was successfully shared with the contacts you provided.

(Bloomberg) — Johnson & Johnson increased its full-year profit and sales forecast after second-quarter profit topped analysts’ estimates, driven by growth in the pharmaceutical division, home to blockbuster products such as arthritis treatment Remicade.

Related: Arthritis: Outcomes vary in disability insurance cases

The shares rose 3.1 percent to $127 at 7:18 a.m. in New York, before the markets opened. The stock has been trading at all-time highs as J&J relies on prescription medicines like Remicade and psoriasis drug Stelara to drive sales and stem a slowdown from the medical devices division. Remicade accounted for about 20 percent of drug revenue for the New Brunswick, New Jersey-based company last quarter.

The world’s biggest maker of health care products raised its earnings forecast to $6.63 to $6.73 a share, excluding some items, from $6.53 to $6.68 previously. Analysts anticipated $6.61.

In the second quarter, earnings were $1.74 a share, excluding some items, compared with the $1.68 average of 20 predictions compiled by Bloomberg. Drug sales increased 8.9 percent during the period, helping offset a decline in consumer products, while revenue from medical devices were little changed.

Here are the highlights for the second-quarter:

Sales were up 3.9 percent to $18.5 billion. Analysts anticipated $18 billion. Net income declined 11 percent to $4 billion, or $1.43 a share, from $4.52 billion, or $1.61 a share

Drug sales:

  • Remicade (arthritis, psoriasis and Crohn’s disease): $1.78 billion, vs. an estimate of $1.71 billion. (4.1 percent better than expected.)

  • Stelara (psoriasis and psoriatic arthritis): $804 million, vs. an estimate of $699 million. (15 percent better than expected.)

  • Zytiga (prostate cancer): $601 million, vs. an estimate of $551.3 million. (9.1 percent better than expected.)

  • Xarelto (blood thinner): $594, vs an estimate of $563.5 million. (%.4 percent better than expected.)

Sales at the consumer business — which includes Johnson’s baby-care products, Neutrogena and Listerine — fell 1.8 percent from the previous year. The company’s medical device sales increased by 0.8 percent versus the previous year

J&J’s shares have almost doubled since the start of 2010 as its drug division sales grew 9 points to 45 percent of revenue. The company has topped earnings estimates every period since the 2010 fourth quarter.


The 10 costliest drugs covered by Medicare Part D

9 conditions to watch for before submitting your app

Have you followed us on Facebook?


© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.